succinic acid has been researched along with Diabetic Neuropathies in 2 studies
Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Succinic Acid has some positive biological properties." | 5.31 | [Diabetes mellitus in the elderly: succinic acid compounds in treating diabetic neuropathies]. ( Belikova, TV; Odin, VI; Pushkova, ES, 2002) |
| "Succinic Acid has some positive biological properties." | 1.31 | [Diabetes mellitus in the elderly: succinic acid compounds in treating diabetic neuropathies]. ( Belikova, TV; Odin, VI; Pushkova, ES, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kharitonova, T | 1 |
| Shvarts, YG | 1 |
| Verbovoy, AF | 1 |
| Orlova, NS | 1 |
| Puzyreva, VP | 1 |
| Strokov, IA | 1 |
| Odin, VI | 1 |
| Belikova, TV | 1 |
| Pushkova, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial of Efficacy and Safety of the Drug Cytoflavin®, Administered Intravenously Followed by Oral Intake, in Patients With Diabetic Polyneuropathy[NCT04649203] | Phase 3 | 216 participants (Actual) | Interventional | 2020-11-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for succinic acid and Diabetic Neuropathies
| Article | Year |
|---|---|
Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (C
Topics: Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Inosine; Male; Niaci | 2022 |
1 other study available for succinic acid and Diabetic Neuropathies
| Article | Year |
|---|---|
[Diabetes mellitus in the elderly: succinic acid compounds in treating diabetic neuropathies].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Male; Middle | 2002 |